Critical success factors for biotechnology industry in Canada

Journal of Commercial Biotechnology

Volumn 13, Issue 2, 2007, Pages 68-77

  Vanderbyl, Sandra ^a   Kobelak, Sherry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSINESS STRUCTURE MODELS; PRODUCT DISTRIBUTION;

INTELLECTUAL PROPERTY; MARKETING; PRODUCT DEVELOPMENT; RISK MANAGEMENT; SUSTAINABLE DEVELOPMENT;

BIOTECHNOLOGY;

ARTICLE; BIOTECHNOLOGY; CANADA; COMMERCIAL PHENOMENA; FINANCIAL MANAGEMENT; GOVERNMENT; KNOWLEDGE MANAGEMENT; MANAGEMENT STYLE; MANPOWER; MARKETING; PATENT; PRODUCT DEVELOPMENT; RISK MANAGEMENT; STRATEGIC PLANNING; SUSTAINABLE DEVELOPMENT;

EID: 34447268728     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3050042     Document Type: Article

References (18)

1. Gader, F. & Spindler, H. (2005). The growth of biotechnology. Ind. Manag. 47, 2.
2. Schultz, L. (2005). Discovery toxicology finds out why good drugs go bad. Drug Discov. Dev. Available at http://www.dddmag.com/ ShowPRPUBCODE~016~ACCT~1600000100~ISSUE~0411~RELTYPE~PR~Prod Code~00000000~PRODLETT~E. html,accessed August 13, 2005.
3. Arojärvi, O. (2001). How to value biotechnology firms: A study of current approaches and value drivers. http://www.finbio.net/download/ progradu-arojarvi-01.pdf, Finnish Bioindustries, accessed 9th Sept 2005.
4. Kulkami, N. (2005). Funds are not a constraint. Biospectrum. http://www.biospectrumindia.com/content/BioTrends/10501061.asp, Biospectrum, accessed 1st Feb 2005.
5. Silverstein, B. & Osbourne, C. (2002). Strategies for attracting healthcare venture capital. J. Commercial Biotechnol. 8(4), 315-319.
6. Tybjee, T. & Hardin, J. (2004) Biotech-pharma alliances: Strategies, structures and financing. J. Commercial Biotechnol. 10(4), 329-339.
7. Canadian Life Sciences Industry Forecast. (2006). Vision of the future. http://www.biotech.ca/PDFs?LifeScienceForecast2006.pdf, Biotech Canada, accessed 22nd Oct 2006.
8. Gustafsson, J. (2000). Risk management in Finnish biopharmaceutical companies. http://www.sal.hut.fi/Publications/pdf-files/tgus00.pdf, Helsinki University of Technology, accessed 9th Sept 2005.
9. Rautiainen, T. (2001). Critical success factors in Biopharmaceutical Business: A comparison between Finnish and Californian businesses. Technology Review 113/2001, http://www.tekes.fi/julkaisut/ Critical_Succes.pdf, Tekes, accessed 9th Sept 2005.
10. Greetham, E. M. (1998). How do you measure 'success' in a biotechnology company. Nat. Biotechnol. 16, 59-60.
11. Statscan. (2003). Overview of biotechnology use and development survey-2003. Statistics Canada. http://www.statcan.ca/bsolc/english/ bsolc?catno=88F0006X200500, Government of Canada, accessed 2nd Oct 2005.
12. Canadian Biotechnology Advisory Committee. (December 2004). Biotechnology and the health of Canadians, http://www.cbac-cccb.ca/ epicinternet/incbac-cccb.nsf/vwap/BHI-Brochure_e.pdf, Government of Canada, accessed 2nd Oct 2005.
13. Kermani, F. & Bonacossa, P. (2003). Current and future prospects for the global biotechnology industry. J. Commercial Biotechnol. 10 2), 154-161.
14. Pavlou, A. (2003). Market place trends in biotherapeutics. J. Commercial Biotechnol. 9(4),358-363.
15. Pavlou, A. (2003). Market place leading biotechnology players, 2002-2008, Key products, indications and technologies. J. Commercial Biotechnol. 10(2), 167-176.
16. Ernest & Young (2005). Competitive Growth, Growing Competition. Beyond Borders 2005. Biotechnology Report 2005. http://www.ey.com/ global/download.nsf/Intenational/Beyond_Borders_ 2005_Competitive_Growth/$file/BeyondBorders 2005CompetitiveGrowthGrowing.pdf.Ernest & Young, accessed 5th Oct 2005.
17. Mirasol, F. (2005). US biotech lead global industry. Chemical Market Reporter. 268, 2.
18. Caron, P., Houle, M. & Rousson, R. (2000). Dynamics between two Canadian industries: Biotechnology and venture capital. http://www.cata.ca/files/pdf/resource_ceters/hightech/reports/ studies/biotech.pdf, Canadian Advanced Technology Alliance, accessed 5th Oct 2005.